{"name":"Joseph L. Kuti, PharmD","slug":"joseph-l-kuti-pharmd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Imipenem, Cilastatin and Relebactam","genericName":"Imipenem, Cilastatin and Relebactam","slug":"imipenem-cilastatin-and-relebactam","indication":"Complicated urinary tract infections (cUTI) including pyelonephritis","status":"marketed"}]}],"pipeline":[{"name":"Imipenem, Cilastatin and Relebactam","genericName":"Imipenem, Cilastatin and Relebactam","slug":"imipenem-cilastatin-and-relebactam","phase":"marketed","mechanism":"Imipenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, cilastatin protects imipenem from renal degradation, and relebactam is a beta-lactamase inhibitor that prevents bacterial resistance.","indications":["Complicated urinary tract infections (cUTI) including pyelonephritis","Complicated intra-abdominal infections (cIAI)","Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQNG9ZdnJTLVhlY1ZJR29nTUFfUW9WdGFmX1RmTmRyOHozT0FUTFhDcWRZLUlNZ0FnSEc0NzNrMnAxVEZzUWQ0SWZmeHBmOTM4V2NwV002WFlIN0FLYkxxTUk1bjZqTnhNVXRyVmVIaGFFOUYzZm1rbGRQNjg1dUpRRHZoYURNZEtvUkdZ?oc=5","date":"2025-05-15","type":"regulatory","source":"The Lancet","summary":"The pharmacokinetics of antibiotics in patients with obesity: a systematic review and consensus guidelines for dose adjustments - The Lancet","headline":"The pharmacokinetics of antibiotics in patients with obesity: a systematic review and consensus guidelines for dose adju","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQZEdvRlpNcWt3U2FoR1p4RTNhRURQSnpKQUdORGpXRV9MaURrbF9LSjRWUlFxZmg1Mi14NjNsQ1RQNnk2TFVzVEhaLURRWFB4QUpnanUtZGhFOFBxOExXVXItTm5jTE9iZG9peVViNEtDUUd4YVlSOWNGeFRlU0JUdm9VMHB6ajFtdHZpS2x1bDNYTllERmdUU1dpM3NmUFlYbGc?oc=5","date":"2018-05-27","type":"pipeline","source":"Loma Linda University","summary":"School of Pharmacy’s graduates encouraged to find value in life beyond work - Loma Linda University","headline":"School of Pharmacy’s graduates encouraged to find value in life beyond work","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOaHZ5ZmlGRGozek1XVDU2RXM3OXk4ZGZld1MzM1IyZm1wakpqUzE3ckFkMnZTVzBpeXo5UWRxY3ZGRVFTMDE1Y1djc0JyQmRHNk8yemtFMzBiWkhRNkptWGVIN0R0N05FQkRIWXktVm1MMjc4YTlLcThZMXR1ZU1lWWRkUFBhR2p3dzVnVFpCMFBGSDFnZXdDdENVRU05bTFR?oc=5","date":"2018-05-11","type":"pipeline","source":"Loma Linda University","summary":"Loma Linda University to graduate nearly 1,500 students in eight ceremonies - Loma Linda University","headline":"Loma Linda University to graduate nearly 1,500 students in eight ceremonies","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}